GLP-1 coverage in Nova Scotia

Nova Scotia Pharmacare is really a family of programs rather than one plan: Family Pharmacare is an income-tested option for residents without private drug insurance, while separate streams cover seniors and people receiving income assistance. Premiums and copays under Family Pharmacare scale with household income.

GLP-1 medications like Ozempic can be covered under these programs when prescribed for type 2 diabetes and approved through Nova Scotia's Exception Status process, which requires a prescriber to document that the patient meets specific clinical criteria before the drug is reimbursed.

Exception Status approval for semaglutide and tirzepatide products in Nova Scotia is tied to the type 2 diabetes indication, not to body weight. A prescription for Wegovy, Saxenda, or an off-label weight-loss use of a diabetes-approved GLP-1 doesn't qualify for reimbursement under Family Pharmacare or any other Nova Scotia public plan.

No provincial public drug plan in Canada currently covers a GLP-1 prescribed specifically for weight loss. Exception Status criteria are reviewed periodically, so confirm current rules with Nova Scotia Pharmacare directly rather than relying on older information.

For Nova Scotians without applicable coverage, Costco Pharmacy is generally the lowest-cost dispensing option nationally, and no membership is needed to use the pharmacy counter. Generic semaglutide has been available since the May 2026 Apotex and Dr. Reddy's launch at roughly $88 to $99/mo nationally; Nova Scotia-specific Costco pricing hasn't been independently verified here.

Brand-name products cost considerably more: Ozempic $250-$310/mo, Wegovy $400-$570/mo, Mounjaro $280-$550/mo, Zepbound $435-$550/mo. About 31% of employer private plans now cover GLP-1s for weight loss, and manufacturer savings cards can lower brand pricing, generally for those who already carry private insurance. Compounded GLP-1 products are not a legal option in Canada.